Type Condition

Clermont, FL

188 Clinical Trials near Clermont, FL

Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Ravulizumab for Lupus Nephritis and IgA Nephropathy

Orlando, Florida
This trial is testing the safety and effectiveness of a drug called ravulizumab, given through a vein, in patients with specific kidney diseases. The drug aims to reduce kidney damage by blocking part of the immune system.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

123 Participants Needed

Medical Cannabis for Chronic Pain

Ocoee, Florida
This trial will investigate if medical cannabis can effectively reduce pain and improve quality of life for patients with chronic conditions. The study will gather data through an online questionnaire about patients' use of cannabis and its effects. Medical cannabis interacts with the body's natural system to help manage pain and other symptoms. Medical cannabis has been increasingly studied and used as an alternative treatment for managing chronic pain, with numerous studies supporting its potential benefits.
Stay on current meds
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:7+

200000 Participants Needed

Encorafenib + Binimetinib for Non-Small Cell Lung Cancer

Tavares, Florida
This is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in combination with binimetinib in patients with BRAFV600E-mutant metastatic non-small cell lung cancer (NSCLC). Patients who are either treatment-naïve, OR who have received 1) first-line treatment with standard platinum-based chemotherapy, OR 2) first-line treatment with an anti-programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) inhibitor given alone or in combination with platinum-based chemotherapy will be enrolled.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

98 Participants Needed

MRTX849 for Cancer

Tavares, Florida
This trial is testing a new pill called MRTX849 (adagrasib) for patients with advanced cancers that have a specific genetic change called KRAS G12C. The pill aims to block this change and stop the cancer from growing. Adagrasib is similar to another approved treatment and is intended for patients with this genetic change who have already received other treatments.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

731 Participants Needed

Targeted Therapy for Cancer

Ocoee, Florida
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and does not respond to treatment (refractory). Patients must have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

6452 Participants Needed

Chemotherapy +/- Erbitux for Breast Cancer

Ocoee, Florida
The purpose of this study is to determine the objective response rates produced by irinotecan and carboplatin therapy with or without Erbitux in patients with Metastatic Breast Cancer.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

154 Participants Needed

Targeted Therapy for Advanced Stage Cancer

Tavares, Florida
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:12+

4200 Participants Needed

Disitamab Vedotin for Breast Cancer

Tavares, Florida
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called disitamab vedotin) for the possible treatment of people with breast cancer that is hard to treat and has spread in the body (advanced cancer). This study is seeking participants who: * have breast cancer that is hard to treat and has spread in the body (advanced cancer) * have tumors that have HER2 on them * have received previous treatment for their advanced breast cancer All participants in this study will receive disitamab vedotin at the study clinic once every 2 weeks as an intravenous (IV) infusion (given directly into a vein). Participants will take the study medicine until they or their doctor decides to stop. This might be because their cancer is getting worse, the study medicine is no longer helping, they have bad side effects, or they wish to stop taking the study medicine. During this time, the participants will have study visits every 2 weeks. After the participants have stopped taking the study medicine, they will have follow-up visits about every 6 weeks unless their cancer gets worse. After that, they will have follow-up phone calls about every 12 weeks. The study team will look at the experiences of people receiving the study medicine. This will help the study team decide if the study medicine is safe and effective.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

100 Participants Needed

LY3871801 for Rheumatoid Arthritis

Ocoee, Florida
The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

380 Participants Needed

AR-14034 for Age-Related Macular Degeneration

Mt. Dora, Florida
The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50+

140 Participants Needed

T-DXd Combinations for Breast Cancer

Leesburg, Florida
DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

245 Participants Needed

ORM-5029 for HER2-Positive Breast Cancer

Nashville, Tennessee
This trial is testing a new drug called ORM-5029 in patients with advanced cancers that have the HER2 protein. The drug aims to find and attack these specific cancer cells. ORM-5029 is being tested for its ability to target HER2-positive cancer cells, a strategy previously explored with other drugs.
No Placebo Group

Trial Details

Trial Status:Terminated
Trial Phase:Phase 1

25 Participants Needed

MicroStent for Peripheral Arterial Disease

Leesburg, Florida
This trial is testing a small tube-like device called the MicroStent® System, used along with a procedure that widens blood vessels, in patients with peripheral arterial disease who have blockages in the arteries below the knee. The stent helps keep the arteries open to ensure better blood flow. The Micro stent (MS) is a balloon expandable stent that allows the treatment of narrowings in distant and twisted coronary arteries.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:21+

177 Participants Needed

DG1 Spectacle Lens for Near-sightedness

Ocoee, Florida
The goal of this clinical trial is to evaluate the safety and efficacy of the DG1 spectacle lens for myopia progression control in children. * To assess if the DG1 lens will slow the progression of myopia through an adjusted mean difference (e.g., age and baseline SER) of approximately 0.75D in cycloplegic spherical equivalent autorefraction refractive error compared to single-vision (SV) spectacles over the study period. * To assess if DG1 lens will slow the progression of myopia through an adjusted mean difference (e.g., age and baseline SER) of approximately 0.3mm in axial elongation compared to SV over the study period. The clinical trial will compare DG1 spectacle lens to single vision spectacle lens. Participants will wear spectacle lenses and return for visits at regularly scheduled intervals through a 36-month follow up visit. All subjects who complete the 36-month visit will continue in the study for an additional 12 months for the rebound evaluation.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:7 - 10

240 Participants Needed

Intraocular Lenses for Cataracts

Mount Dora, Florida
A study to evaluate the real-world clinical performance of the enVista Aspire and Aspire Toric intraocular lens (IOL) models EA and ETA and to assess surgeon and subject satisfaction
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:22+

450 Participants Needed

Endoscopic Therapy for Type 2 Diabetes

Ocoee, Florida
This study is designed to evaluate the safety and effectiveness of endoscopic intestinal re-cellularization therapy in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering medications.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:22 - 70

264 Participants Needed

Overnight Orthokeratology Lenses for Near-Sightedness

Ocoee, Florida
The objective of this clinical investigation is to collect scientifically valid safety and effectiveness data on the Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear. The clinical performance data reported from this study is intended to be submitted to the U.S. Food and Drug Administration Center for Devices and Radiological Health (CDRH) in support of a new Premarket Application (PMA).
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:7+

387 Participants Needed

MiSight 1 Day Contact Lenses for Nearsightedness

Ocoee, Florida
This trial is testing special contact lenses called MiSight 1 Day to see if they can slow down worsening nearsightedness in children. The study will also check if the benefits last after stopping the treatment. The lenses work by changing how light enters the eye to slow down eye growth. MiSight 1 Day contact lenses have been shown to slow myopia progression in children over several years.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:8 - 12

900 Participants Needed

New Infant Formula + Toddler Drink for Growth Development

Apopka, Florida
This trial is testing a new baby formula and toddler drink to see how they affect the growth and development of infants by providing essential nutrients.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:0 - 14

607 Participants Needed

LINQ Sensor Algorithm for Heart Failure

Leesburg, Florida
This trial tests a small device that monitors heart activity in patients with moderate heart failure. The device uses special software to help doctors manage patient care more effectively.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

826 Participants Needed

Why Other Patients Applied

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

Adjunctive Troriluzole for OCD

Apopka, Florida
This trial is testing a new medication called troriluzole to see if it helps people with OCD who aren't getting enough relief from their current treatments. Troriluzole is added to their existing medications and works by changing brain chemicals to reduce OCD symptoms. Troriluzole is related to riluzole, which has shown benefits in treating OCD when used alongside existing treatments.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Age:18 - 65

700 Participants Needed

Orforglipron for Type 2 Diabetes

Ocoee, Florida
This trial is testing a new medication called orforglipron to help adults with type 2 diabetes who can't control their blood sugar with diet and exercise alone. The medication aims to improve how the body manages sugar levels.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting

520 Participants Needed

Estetrol for Sexual Dysfunction

Ocoee, Florida
This trial is testing estetrol, a hormone treatment, in postmenopausal women with sexual arousal disorder. The goal is to see if estetrol can help by balancing hormone levels. Participants will take estetrol for a few months and their progress will be monitored. Estetrol has been studied for its potential in hormone therapy, showing improvements in postmenopausal women.

Trial Details

Trial Status:Active Not Recruiting
Age:40 - 65
Sex:Female

82 Participants Needed

Deucravacitinib for Lupus

Orlando, Florida
This trial is testing a new medication called BMS-986165 to see if it is safe and can be tolerated by people with Systemic Lupus Erythematosus (SLE).
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

261 Participants Needed

MR-100A-01 for Birth Control

Leesburg, Florida
This trial is studying a birth control patch called MR-100A-01 in women. The patch contains hormones that prevent pregnancy by stopping ovulation and making it harder for sperm to reach eggs. The study will look at how well the patch works, how it affects menstrual cycles, and its safety and tolerability. The MR-100A-01 patch is similar to other transdermal contraceptive patches that have been studied for their effectiveness in preventing ovulation and controlling menstrual cycles.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Age:16 - 35
Sex:Female

1321 Participants Needed

BRIMOCHOL + Carbachol for Presbyopia

Mount Dora, Florida
This trial tests eye drops called BRIMOCHOL™ PF and Carbachol PF. It targets people who have trouble seeing things up close due to aging. The drops aim to improve their close-up vision by working on the eye's muscles or structures.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Age:45 - 80

450 Participants Needed

Finerenone + Empagliflozin for Chronic Kidney Disease and Type 2 Diabetes

Ocoee, Florida
This trial tests if combining finerenone and empagliflozin can better slow down kidney damage in patients with CKD and T2D compared to using each drug alone. Finerenone protects kidneys, while empagliflozin lowers blood sugar. Empagliflozin has shown significant improvements in glycemic control, body weight, and blood pressure, and finerenone has demonstrated improved outcomes in patients with chronic kidney disease and type 2 diabetes. The study will measure protein levels in urine to assess effectiveness.

Trial Details

Trial Status:Active Not Recruiting

1664 Participants Needed

Anti-Factor XI Monoclonal Antibody for Kidney Failure

Orlando, Florida
This trial is testing MK-2060, a medicine that blocks a blood protein, on patients with severe kidney disease. The goal is to see if it can prevent clots and keep the treatment method effective for a longer period.

Trial Details

Trial Status:Active Not Recruiting

506 Participants Needed

DONQ52 for Celiac Disease

Leesburg, Florida
This trial is testing a new drug called DONQ52 in patients with well-managed celiac disease. The study has two parts: one where patients receive single doses and another where they receive multiple doses. The goal is to see if the drug is safe and well-tolerated.

Trial Details

Trial Status:Active Not Recruiting

56 Participants Needed

DMR for Type 2 Diabetes

Ocoee, Florida
The Revita® system is being investigated to assess the efficacy of DMR versus Sham on improvement in Glycemic, Hepatic and Cardiovascular endpoints for patients with Type 2 Diabetes who are inadequately controlled on one or more glucose lowering agents. The purpose of this study is to demonstrate the efficacy and safety of the Fractyl DMR Procedure using the Revita® System compared to a sham. Subjects randomized to the DMR procedure will be followed per protocol till 48 weeks post treatment. Subjects in the Sham treatment arm will be offered cross over to receive the DMR treatment at 48 weeks and will be followed per protocol for 48 weeks post treatment.

Trial Details

Trial Status:Recruiting
Age:21 - 70

320 Participants Needed

1...567

Know someone looking for new options? Spread the word

Match to a Trial